Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6129 in Relapsed or Refractory Multiple Myeloma
NCT05308225Phase 2Active, not recruiting
- Sponsor
- Sorrento Therapeutics
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of STI-6129 in multiple myeloma (MM), sponsored by Sorrento Therapeutics. Primary endpoint: Safety of STI-6129 up to 24 months. Started Feb 2023; status: active, not recruiting.
02
Drugs
STI-6129
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05308225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05308225.